KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Pacific Biosciences Of California (PACB) EBT Margin (2016 - 2026)

Pacific Biosciences Of California has reported EBT Margin over the past 16 years, most recently at 89.97% for Q4 2025.

  • For Q4 2025, EBT Margin fell 9682.0% year-over-year to 89.97%; the TTM value through Dec 2025 reached 341.28%, down 14030.0%, while the annual FY2025 figure was 341.28%, 14030.0% down from the prior year.
  • EBT Margin for Q4 2025 was 89.97% at Pacific Biosciences Of California, up from 97.86% in the prior quarter.
  • Over five years, EBT Margin peaked at 6.85% in Q4 2024 and troughed at 1147.62% in Q1 2025.
  • A 5-year average of 229.61% and a median of 151.94% in 2024 define the central range for EBT Margin.
  • On a YoY basis, EBT Margin climbed as much as 37591bps in 2025 and fell as far as -94619bps in 2025.
  • Year by year, EBT Margin stood at 189.22% in 2021, then crashed by -63bps to 308.5% in 2022, then skyrocketed by 54bps to 141.78% in 2023, then skyrocketed by 105bps to 6.85% in 2024, then plummeted by -1413bps to 89.97% in 2025.
  • Business Quant data shows EBT Margin for PACB at 89.97% in Q4 2025, 97.86% in Q3 2025, and 105.35% in Q2 2025.